A further mechanism of ESE transcription factor suppression in cancer is via promoter methylation, which has been reported for EHF in prostate [80] and pancreatic cancer [84], and for ELF5 in bladder cancer [61]. This evidence concerns the gene ELF5 and urinary bladder cancer.